company background image
PSNL logo

Personalis NasdaqGM:PSNL Stock Report

Last Price

US$1.26

Market Cap

US$61.8m

7D

5.4%

1Y

-60.4%

Updated

21 Feb, 2024

Data

Company Financials +

Personalis, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Personalis
Historical stock prices
Current Share PriceUS$1.26
52 Week HighUS$3.27
52 Week LowUS$0.89
Beta1.93
1 Month Change-21.74%
3 Month Change-8.03%
1 Year Change-60.38%
3 Year Change-96.37%
5 Year Changen/a
Change since IPO-95.58%

Recent News & Updates

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Dec 18
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Dec 04
Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Recent updates

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Dec 18
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Dec 04
Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely

Sep 04
Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely

Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)

Apr 17
Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)

The Prognosis For Personalis

Jun 16

Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Jun 09
Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Is Personalis (NASDAQ:PSNL) Using Debt In A Risky Way?

Feb 17
Is Personalis (NASDAQ:PSNL) Using Debt In A Risky Way?

Personalis: Getting Personal Again

Feb 02

Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Nov 11
Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth

Oct 12
Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth

We're Hopeful That Personalis (NASDAQ:PSNL) Will Use Its Cash Wisely

Jul 05
We're Hopeful That Personalis (NASDAQ:PSNL) Will Use Its Cash Wisely

Personalis: Market-Leading Immuno-Oncology Platform Drives Consistent Long-Term Growth

Jun 21

Personalis EPS beats by $0.07, beats on revenue

May 05

Personalis (NASDAQ:PSNL) Is In A Good Position To Deliver On Growth Plans

Apr 05
Personalis (NASDAQ:PSNL) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

PSNLUS Life SciencesUS Market
7D5.4%-1.1%-0.5%
1Y-60.4%-0.5%22.3%

Return vs Industry: PSNL underperformed the US Life Sciences industry which returned -2.6% over the past year.

Return vs Market: PSNL underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is PSNL's price volatile compared to industry and market?
PSNL volatility
PSNL Average Weekly Movement17.1%
Life Sciences Industry Average Movement7.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: PSNL's share price has been volatile over the past 3 months.

Volatility Over Time: PSNL's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011397Chris Hallhttps://www.personalis.com

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.

Personalis, Inc. Fundamentals Summary

How do Personalis's earnings and revenue compare to its market cap?
PSNL fundamental statistics
Market capUS$61.78m
Earnings (TTM)-US$112.78m
Revenue (TTM)US$70.53m

0.9x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PSNL income statement (TTM)
RevenueUS$70.53m
Cost of RevenueUS$55.21m
Gross ProfitUS$15.32m
Other ExpensesUS$128.10m
Earnings-US$112.78m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 28, 2024

Earnings per share (EPS)-2.30
Gross Margin21.71%
Net Profit Margin-159.91%
Debt/Equity Ratio0.3%

How did PSNL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.